Lattice Medical has successfully secured $43,000,000 in its latest funding round. This substantial capital infusion is poised to significantly strengthen the company’s operational capabilities and accelerate its strategic initiatives within the medical technology sector.
The company specializes in tissue engineering and 3D printing, focusing on the development of innovative implants for soft tissue regeneration using advanced biomaterials. Lattice Medical’s foundational aim is to provide patients with enhanced quality of care through cutting-edge medical devices. Its current portfolio highlights two key innovations: MATTISSE, a 3D-printed resorbable breast implant, and RODIN, a matrix specifically designed for regenerating the hypodermis. These products underscore the company’s commitment to advancing regenerative medicine and offering improved therapeutic options for soft tissue repair.
The newly raised capital will be primarily directed towards accelerating the development and potential commercialization of these advanced regenerative medical solutions. Specifically, the funds are expected to support expanded research and development efforts, enabling the company to further refine its technologies and explore new applications. It will also facilitate comprehensive clinical trials essential for regulatory approvals and market access, alongside scaling manufacturing capabilities to meet anticipated future demand. This investment underscores investor confidence in Lattice Medical’s proprietary technology and its potential to address critical, unmet medical needs for patients globally.
This funding round represents a pivotal moment for Lattice Medical, enabling it to transition its innovative solutions towards broader clinical adoption. The company plans to leverage this investment to further expand its product pipeline and solidify its market presence. By continuing to advance its regeneration solutions, Lattice Medical aims to make its transformative technologies accessible to a wider patient population, ultimately contributing to improved standards of care and the ongoing evolution of medical treatment options.
